Skip to content
2000
Volume 7, Issue 6
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagon- like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.

Loading

Article metrics loading...

/content/journals/cdr/10.2174/157339911797579160
2011-11-01
2025-05-18
Loading full text...

Full text loading...

/content/journals/cdr/10.2174/157339911797579160
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test